Abstracts tagged "rheumatoid arthritis"

Abstract Number: 441 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor: Safety Comparison In Patients With Rheumatoid Arthritis and An Inadequate Response To Nonbiologic Or Biologic Disease‑Modifying Anti-Rheumatic Drugs
G. R. Burmester¹, C Charles-Schoeman², J. D. Isaacs³, T. Hendrikx⁴, K. Kwok⁵, S. H. Zwillich⁶ and R. Riese⁶, ¹Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Charité University Medicine Berlin, Berlin, Germany, ²University of California, Los Angeles, CA, ³Newcastle University, Newcastle-upon-Tyne, United Kingdom, ⁴Pfizer BV, Capelle aan den IJssel, Netherlands, ⁵Pfizer Inc, New York, NY, ⁶Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis provides comparative safety data on the incidence…
Abstract Number: 2801 • 2013 ACR/ARHP Annual Meeting
Comparative Longitudinal Analysis Of Periarticular Bone Structure In Patients Treated With Methotrexate In Combination Of Either TNF Blockers Or Tocilizumab
Sebastian Kraus¹, Matthias Englbrecht¹, Juergen Rech², Roland Kocijan¹, Georg A. Schett¹ and Stephanie Finzel¹, ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Inhibition of tumor necrosis factor alpha (TNFi) and interleukin-6 receptor (IL6Ri, tocilzumab) are among the most potent therapeutic strategies in patients with rheumatoid arthritis…
Abstract Number: 2330 • 2013 ACR/ARHP Annual Meeting
Relationship Between Lymphocyte Count and Risk Of Infection In Rheumatoid Arthritis Patients Treated With Tofacitinib
R. F. van Vollenhoven¹, R. Riese², S. Krishnaswami², T. Kawabata², C. Fosser², S. Rottinghaus², M. Lamba² and S. H. Zwillich², ¹Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, ²Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Cytokines involved in lymphocyte development, function and homeostasis…
Abstract Number: 1391 • 2013 ACR/ARHP Annual Meeting
Transporters As Drug Gateway Into The Cell For Specific Targeting Of Tyrosine Kinase Signaling Pathway In Rheumatoid Arthritis
Saliha Harrach¹, Christian Schmidt-Lauber², Bayram Edemir³, Eberhard Schlatter¹, Thomas Pap⁴, Giuliano Ciarimboli¹ and Jessica Bertrand², ¹Experimental Nephrology, Medical Clinic und Policlinic D, University Hospital Münster, Münster, Germany, ²Institute of Experimental Musculoskeletal Medicine (IEMM), University Hospital Münster, Münster, Germany, ³Experimental Nephrology, Medical Clinic und Policlinic D, University Hospital Münster, Muenster, Germany, ⁴Institute of Experimental Muskuloskeletal Medicine, University Hospital Münster, Münster, Germany
Background/Purpose: Tyrosine kinase inhibitors (TKI) are effective in treating malignant disorders and were suggested to also have an impact on non-malignant diseases such as rheumatoid…
Abstract Number: 442 • 2013 ACR/ARHP Annual Meeting
Tolerability and Non-Serious Adverse Events In Rheumatoid Arthritis Patients Treated With Tofacitinib As Monotherapy Or In Combination Therapy
A. Dikranian¹, K. Soma², R. Riese², D. Gruben² and T. V. Jones³, ¹San Diego Arthritis Medical Clinic, San Diego, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Tolerability remains an ill-defined construct in clinical trials.…
Abstract Number: 2767 • 2013 ACR/ARHP Annual Meeting
Tocilizumab In Combination Therapy and Monotherapy Versus Methotrexate In Methotrexate-Naive Patients With Early Rheumatoid Arthritis: Clinical and Radiographic Outcomes From a Randomized, Placebo-Controlled Trial
Gerd Burmester¹, William Rigby², Ronald F. van Vollenhoven³, Jonathan Kay⁴, Andrea Rubbert-Roth⁵, Ariella Kelman⁶, Sophie Dimonaco⁷ and Nina Mitchell⁷, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Dartmouth-Hitchcock Medical Center and Dartmouth Medical School, Lebanon, NH, ³Karolinska Institute, Stockholm, Sweden, ⁴UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, ⁵University of Cologne, Cologne, Germany, ⁶Genentech, South San Francisco, CA, ⁷Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: Recent recommendations support intensive treatment of patients (pts) with early rheumatoid arthritis (RA) to achieve remission or low disease activity.1-3 Tocilizumab (TCZ) was not…
Abstract Number: 2234 • 2013 ACR/ARHP Annual Meeting
Targeting Therapy Of Citrullinated Antigen-Specific B Cells Ameliorates Collagen-Induced Arthritis
Kazuya Michishita¹, Kimito Kawahata¹, Takeyuki Kanzaki², Lisa Akahira¹, Toshiki Eri¹ and Kazuhiko Yamamoto³, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Internal Medicine, Yamanashi Prefectural Central Hospital, Yamanashi, Japan, ³Department of Allergy and Rhaumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Background/Purpose: The clinical benefit of B-cell depletion therapy in rheumatoid arthritis(RA) is a well-known fact, but problems such as relapse of tuberculosis and reactivation of…
Abstract Number: 1374 • 2013 ACR/ARHP Annual Meeting
NR1D1 Is a New Suppressor of Rheumatoid Arthritis Fibroblast-Like Synoviocyte Invasion
Teresina Laragione^1,2 and Percio Gulko^1,2, ¹Center for Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ²Molecular Medicine, Hosftra North Shore-LIJ School of Medicine, Manhasset, NY
Background/Purpose: Rheumatoid arthritis (RA) is a common and chronic autoimmune disease. Arthritis severity and joint damage predict clinical outcome and the risk for disability in…
Abstract Number: 443 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Analyses Of Tofacitinib From Pooled Phase 2, Phase 3 and Long-Term Extension Rheumatoid Arthritis Studies: US Compared With Non-US Populations
S. B. Cohen¹, Roy Fleischmann¹, J. M. Kremer², A. Koenig³, K. Kwok⁴, L. Wang⁵, C. a. Mebus⁵, R. Riese⁵ and T. Robinson³, ¹Metroplex Clinical Research Center, Dallas, TX, ²Albany Medical College and The Center for Rheumatology, Albany, NY, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor approved in the US for the treatment of rheumatoid arthritis at 5 mg BID. Phase (P) 3…
Abstract Number: 2644 • 2013 ACR/ARHP Annual Meeting
Phase IB/Iia Study On Intravenous Administration Of Expanded Allogeneic Adipose-Derived Mesenchymal Stem Cells In Refractory Rheumatoid Arthritis Patients
JM Alvaro-Gracia¹, Juan A. Jover², Rosario Garcia-Vicuña³, Luis Carreño⁴, Alberto Alonso⁵, Sara Marsal⁶, Francisco J. Blanco⁷, Víctor M. Martínez-Taboada⁸, Peter C. Taylor⁹, Federico Díaz-González¹⁰ and Lydia Dorrego¹¹, ¹Unidad de Terapias Biológicas. Servicio de Reumatología, Hospital Universitario de La Princesa, Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ³Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁴Rheumatology, Gregorio Marañón Hospital, Madrid, Spain, ⁵Hospital de Cruces, Bilbao, Spain, ⁶Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ⁷INIBIC-Hospital Universitario A Coruña. Rheumatology Division. Genomic Group, A Coruña, Spain, ⁸Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV., Santander, Spain, ⁹NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ¹⁰Hospital Universitario de Canarias, La Laguna. Tenerife, Spain, ¹¹TiGenix, Tres Cantos, Spain
Background/Purpose: Expanded adipose-derived stem cells (eASCs) are shown to have immune-modulatory effects both in vitro and in animal models of arthritis. eASCs are currently under…
Abstract Number: 2213 • 2013 ACR/ARHP Annual Meeting
Anti-IL-6 Receptor Antibody Normalizes Both DKK-1 and Sclerostin As Wnt Inhibitors In a Mouse Model Of Collagen-Induced Arthritis
Hiroto Yoshida¹, Mika Yagoto¹, Miho Suzuki¹, Keisuke Tanaka¹, Isao Matsumoto², Takayuki Sumida³ and Yoshihiro Matsumoto¹, ¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ²Department of Internal Medicine, Faculty of Medicine,, University of Tsukuba, Tsukuba, Japan, ³Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: The Wnt pathway plays an important role in bone formation and regeneration. This pathway is regulated by several soluble inhibitors such as Dickkopf-1 (DKK-1)…
Abstract Number: 1373 • 2013 ACR/ARHP Annual Meeting
Connective Tissue Growth Factor Promotes Angiogenesis Through Increased Notch-1 Signaling in Rheumatoid Arthritis
Kazuhisa Nozawa¹, Maki Fujishiro², Ayako Yamaguchi¹, Mikiko Kawasaki², Kazuhisa Iwabuchi², Mitsuaki Yanagida², Keigo Ikeda³, Shinji Morimoto⁴, Yoshinari Takasaki⁵ and Iwao Sekigawa³, ¹Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Institute for Environment and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan, ³Internal Medicine 2, Juntendo University Urayasu Hospital, Tomioka, Urayasu, Chiba, Japan, ⁴Juntendo University Urayasu Hospital, Tokyo, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Juntendo University, Tokyo, Japan
Background/Purpose: Increased angiogenesis has been associated with various inflammatory disease states including rheumatoid arthritis (RA), and it has been considered as one of main factors…
Abstract Number: 444 • 2013 ACR/ARHP Annual Meeting
Reversibility Of Pharmacodynamic Effects After Short- and Long-Term Treatment With Tofacitinib In Patients With Rheumatoid Arthritis
M. C. Genovese¹, T. Kawabata², K. Soma², S. Menon², J.D. Clark³, J. Hodge⁴, L. Takiya⁴, R. Riese² and S. Krishnaswami⁵, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Cambridge, MA, ⁴Pfizer Inc, Collegeville, PA, ⁵Clinical Pharmacology, Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). It has a short pharmacokinetic (PK) half-life of…
Abstract Number: 1947 • 2012 ACR/ARHP Annual Meeting
Muscle Wasting in HTNFtg Mice, an Animal Model for Rheumatoid Arthritis, Due to Increased Cathepsin L and LC3B Expression
Martin Willburger¹, Birgit Niederreiter¹, Ewald Unger², Josef S. Smolen³, Kurt Redlich¹ and Silvia Hayer¹, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Center for Medical Physics and Biomedicla Engineering, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: To investigate the impact of systemic inflammation on skeletal muscles in human tumor necrosis factor transgenic (hTNFtg) animals. Methods: We isolated triceps surae, quadriceps,…
Abstract Number: 1294 • 2012 ACR/ARHP Annual Meeting
A Phase Ib Multiple Ascending Dose Study Evaluating Safety, Pharmacokinetics, and Early Clinical Response of Brodalumab (AMG 827), a Human Anti-Interleukin 17 Receptor (IL-17R) Antibody, in Rheumatoid Arthritis
Melvin A. Churchill¹, Luis F. Flores-Suarez², Daniel J. Wallace³, Kristine Phillips⁴, Richard W. Martin⁵, Mario H. Cardiel⁶, Jeffrey Kaine⁷, Edgar Bautista⁸, David H. Salinger⁹, Erin Stevens⁹, Christopher B. Russell⁹ and David A. Martin⁹, ¹Arthritis Center of Nebraska, Lincoln, NE, ²Primary Systemic Vasculitides Clinic, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Rheumatology, University of Michigan Medical School, Ann Arbor, MI, ⁵Medicine, Rheumatology, Michigan State University College of Human Medicine, Grand Rapids, MI, ⁶Research Unit, Hospital, Morelia, Mexico, ⁷Sarasota Arthritis Research Center, Sarasota, FL, ⁸Medical Sciences, Amgen, Thousand Oaks, CA, ⁹Medical Sciences, Amgen, Seattle, WA
Background/Purpose: The cytokine IL-17A is an innate inflammatory cytokine implicated in the pathogenesis of several human autoimmune diseases including rheumatoid arthritis (RA). Brodalumab is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].